CN101883580B - 水产用亚单位疫苗 - Google Patents
水产用亚单位疫苗 Download PDFInfo
- Publication number
- CN101883580B CN101883580B CN2007801018481A CN200780101848A CN101883580B CN 101883580 B CN101883580 B CN 101883580B CN 2007801018481 A CN2007801018481 A CN 2007801018481A CN 200780101848 A CN200780101848 A CN 200780101848A CN 101883580 B CN101883580 B CN 101883580B
- Authority
- CN
- China
- Prior art keywords
- protein
- seq
- albumen
- sequence
- pet24a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000009360 aquaculture Methods 0.000 title abstract description 6
- 244000144974 aquaculture Species 0.000 title abstract description 6
- 229940031626 subunit vaccine Drugs 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 97
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 87
- 102000036639 antigens Human genes 0.000 claims abstract description 58
- 108091007433 antigens Proteins 0.000 claims abstract description 57
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 21
- 239000002671 adjuvant Substances 0.000 claims abstract description 15
- 229960005486 vaccine Drugs 0.000 claims description 46
- 238000004581 coalescence Methods 0.000 claims description 35
- 241000700605 Viruses Species 0.000 claims description 26
- 101710081079 Minor spike protein H Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims description 11
- 210000000496 pancreas Anatomy 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 230000017074 necrotic cell death Effects 0.000 claims description 8
- 101710136297 Protein VP2 Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims 6
- 208000010824 fish disease Diseases 0.000 abstract description 15
- 239000000969 carrier Substances 0.000 abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 210000002706 plastid Anatomy 0.000 description 37
- 239000000047 product Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 238000003752 polymerase chain reaction Methods 0.000 description 28
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 27
- 241000972773 Aulopiformes Species 0.000 description 21
- 235000019515 salmon Nutrition 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 230000000890 antigenic effect Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000009471 action Effects 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 230000002458 infectious effect Effects 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 6
- 229940023064 escherichia coli Drugs 0.000 description 6
- 235000019688 fish Nutrition 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 description 5
- 241001492212 Striped Jack nervous necrosis virus Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000000751 protein extraction Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010058096 Pancreatic necrosis Diseases 0.000 description 4
- 241000277263 Salmo Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 101710082714 Exotoxin A Proteins 0.000 description 3
- 101710121996 Hexon protein p72 Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 description 3
- 238000011951 anti-virus test Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101900217743 Infectious pancreatic necrosis virus Capsid protein VP2 Proteins 0.000 description 2
- 241000701372 Iridovirus Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 101150084101 RNA2 gene Proteins 0.000 description 2
- 101100353432 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRP2 gene Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 241001275829 Squaliobarbus Species 0.000 description 2
- 208000001449 Viral Hemorrhagic Septicemia Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000036569 Carp sprivivirus Species 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000593470 Grouper iridovirus Species 0.000 description 1
- 241000442132 Lactarius lactarius Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000606416 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Acyltransferase PE Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000277289 Salmo salar Species 0.000 description 1
- 241001223864 Sphyraena barracuda Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2007/003438 WO2009070929A1 (fr) | 2007-12-04 | 2007-12-04 | Vaccin sous-unité pour l'aquaculture |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101883580A CN101883580A (zh) | 2010-11-10 |
CN101883580B true CN101883580B (zh) | 2013-12-25 |
Family
ID=40717262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007801018481A Expired - Fee Related CN101883580B (zh) | 2007-12-04 | 2007-12-04 | 水产用亚单位疫苗 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8343505B2 (zh) |
JP (1) | JP5132780B2 (zh) |
CN (1) | CN101883580B (zh) |
CA (1) | CA2707919C (zh) |
GB (1) | GB2467722B (zh) |
NO (1) | NO20100811L (zh) |
WO (1) | WO2009070929A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101883580B (zh) | 2007-12-04 | 2013-12-25 | 施怀哲维克有限公司 | 水产用亚单位疫苗 |
UA113192C2 (xx) * | 2011-12-06 | 2016-12-26 | Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2) | |
GB201309664D0 (en) * | 2013-05-30 | 2013-07-17 | Univ Aberdeen | Fish vaccine |
MY181007A (en) * | 2013-05-31 | 2020-12-15 | Intervet Int Bv | Scale drop disease (sdd) causative virus and derivatives thereof |
CA2985381C (en) * | 2015-06-01 | 2020-03-24 | Reber Genetics Co., Ltd. | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases |
US20210368745A1 (en) * | 2017-12-21 | 2021-12-02 | Gis Gas Infusion Systems Inc. | Method and apparatus for fish farms |
CN116510001B (zh) * | 2023-06-26 | 2023-11-24 | 西北农林科技大学深圳研究院 | 一种水产养殖用mRNA疫苗及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1161862A (zh) * | 1996-12-27 | 1997-10-15 | 中国科学院水生生物研究所 | 蛙病毒疫苗 |
CN1311036A (zh) * | 2000-02-29 | 2001-09-05 | 中国科学院南海海洋研究所 | 一种抗海水养殖动物弧菌病的混合疫苗及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1075523B1 (en) * | 1998-05-08 | 2007-08-08 | Intervet International BV | Structural proteins of fish pancreatic disease virus and uses thereof |
JP3681933B2 (ja) * | 1999-09-29 | 2005-08-10 | 三郎 原 | ビルナウイルスサブユニットワクチン |
US7807144B2 (en) * | 2001-09-05 | 2010-10-05 | Academia Sinica | Oral vaccines |
AU2003229199A1 (en) * | 2002-05-31 | 2003-12-19 | Alpharma As | Liposome vaccine formulations for fin-fish |
US20040024761A1 (en) * | 2002-07-13 | 2004-02-05 | Kolbe Steven J. | Web-besed, industry specific, staffing interactive database |
WO2004026338A1 (en) * | 2002-09-17 | 2004-04-01 | Novartis Ag | Ihnv g protein for immune stimulation |
TWI350310B (en) * | 2002-12-13 | 2011-10-11 | Novartis Ag | Immunization of fish with plant-expressed recombinant proteins |
US7335361B2 (en) * | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
US20070243587A1 (en) * | 2006-04-14 | 2007-10-18 | Healthbanks Biotech Co., Ltd. | Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus |
CN101883580B (zh) | 2007-12-04 | 2013-12-25 | 施怀哲维克有限公司 | 水产用亚单位疫苗 |
-
2007
- 2007-12-04 CN CN2007801018481A patent/CN101883580B/zh not_active Expired - Fee Related
- 2007-12-04 US US12/746,409 patent/US8343505B2/en active Active
- 2007-12-04 CA CA2707919A patent/CA2707919C/en not_active Expired - Fee Related
- 2007-12-04 JP JP2010536304A patent/JP5132780B2/ja not_active Expired - Fee Related
- 2007-12-04 WO PCT/CN2007/003438 patent/WO2009070929A1/zh active Application Filing
- 2007-12-04 GB GB1010584.9A patent/GB2467722B/en active Active
-
2010
- 2010-06-04 NO NO20100811A patent/NO20100811L/no unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1161862A (zh) * | 1996-12-27 | 1997-10-15 | 中国科学院水生生物研究所 | 蛙病毒疫苗 |
CN1311036A (zh) * | 2000-02-29 | 2001-09-05 | 中国科学院南海海洋研究所 | 一种抗海水养殖动物弧菌病的混合疫苗及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
GB2467722B (en) | 2012-03-07 |
WO2009070929A1 (fr) | 2009-06-11 |
CA2707919A1 (en) | 2009-06-11 |
NO20100811A (no) | 2010-08-27 |
US8343505B2 (en) | 2013-01-01 |
NO20100811L (no) | 2010-08-27 |
GB2467722A (en) | 2010-08-11 |
CA2707919C (en) | 2014-02-11 |
GB201010584D0 (en) | 2010-08-11 |
US20100316663A1 (en) | 2010-12-16 |
CN101883580A (zh) | 2010-11-10 |
JP2011505391A (ja) | 2011-02-24 |
JP5132780B2 (ja) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111217917B (zh) | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 | |
CN101883580B (zh) | 水产用亚单位疫苗 | |
CN103007273B (zh) | 一种口蹄疫基因工程混合表位疫苗及其制备方法 | |
CN104873967A (zh) | O型口蹄疫病毒样颗粒疫苗及其制备方法和应用 | |
CN101880647B (zh) | 重组猪霍乱沙门氏菌及二价基因工程疫苗与应用 | |
CN108823218A (zh) | 鸡传染性法氏囊病病毒vp2基因、其表达产物、其亚单位疫苗及应用 | |
CN104292339A (zh) | 含sars病毒rbd抗原的重组蛋白及展示rbd蛋白的杆状病毒 | |
CN109467606A (zh) | 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用 | |
CN102274496B (zh) | 一种O/Asia I型口蹄疫病毒两价基因工程多肽疫苗及制备方法和用途 | |
CN104628871B (zh) | 一种重组法氏囊病蛋白工程疫苗的制备 | |
CN102816246A (zh) | 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途 | |
CN102416174A (zh) | 猪o型口蹄疫重组噬菌体疫苗及其构建方法 | |
EP1334197B1 (en) | Yeast derived vaccine against ipnv | |
CN104250304B (zh) | 一种融合蛋白及其编码的疫苗组合物与应用 | |
KR101919002B1 (ko) | 구제역 바이러스의 가용성 다가 항원단백질 및 이의 용도 | |
CN104610455A (zh) | 一种鸭坦布苏病毒基因工程亚单位疫苗 | |
CN107446872A (zh) | 一种组成型表达兔病毒性出血症病毒vp60蛋白的重组乳酸菌疫苗株及其制备方法和用途 | |
CN102406929A (zh) | 一种共表达分子佐剂加强型二价口蹄疫蛋白工程疫苗 | |
CN116785418A (zh) | 一种鱼源无乳链球菌亚单位疫苗及其制备方法与应用 | |
CN110101854B (zh) | 一种鲤疱疹病毒ⅲ型疫苗及其制备方法 | |
CN109195624A (zh) | Hev疫苗 | |
CN111840533B (zh) | A型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用 | |
CN113563432A (zh) | 口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用 | |
CN107827986B (zh) | 猪O/Mya98和O/PanAsia型口蹄疫基因工程灭活疫苗 | |
WO2005021035A1 (fr) | Vaccin peptidique bivalent dirige contre fmd, ses procedes de preparation et ses applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SBC VIRBAC CO., LTD. Free format text: FORMER OWNER: SCHWEITZER CO., LTD. Effective date: 20131121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: TAIWAN, CHINA TO: HONG KONG, CHINA |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20131121 Address after: Room 2, 2201-2207, Times Square, 1 don't street, Hongkong, Tongluowan, China Applicant after: Schweitzer Biotech Company Ltd Address before: China Taiwan Taipei City crest Avenue Neihu Technology Park two 4 floor, No. 501 Applicant before: Schweitzer Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131225 Termination date: 20201204 |
|
CF01 | Termination of patent right due to non-payment of annual fee |